Suraksha Diagnostic Ltd IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow

Suraksha Diagno.

CMP

417.25

-23.75 (-5.39%)

  • DRHP
₹441

Offer Price

₹ 846.25 Cr

Issue Size

₹ 14,994

Min Investment

1.27x

Times Subscribed

34

Lot size

Time Line

  • 29
    Nov 2024
    Open
  • 03
    Dec 2024
    Close
  • 04
    Dec 2024
    Finalisation of Basis of Allotment
  • 05
    Dec 2024
    Initiation of Refunds
  • 05
    Dec 2024
    Transfer of Shares to Demat Account
  • 06
    Dec 2024
    Listing Date

Shares Offered

Number of Times Subscribed

Objects of the Offer

  • Strengthen our position in our core geography i.e. Kolkata and the rest of West Bengal.

  • Expand beyond our core markets in adjacent geographies of eastern and north-eastern India.

  • Supplement organic growth with selective acquisitions.

  • Leverage technology to elevate customer experience.

  • Augmenting medical consultation services offered through polyclinic chambers at our diagnostic centres to boost our revenue.

Strengths

  • Diagnostic chain with in eastern India well positioned to leverage growth opportunity for organized diagnostic chains in the diagnostic services markets in eastern and north-eastern India.

  • Track record of profitability and financial performance.

  • Integrated diagnostics provider with one-stop solution offering pathology and radiology testing, and medical consultation services.

  • Technologically advanced clinical infrastructure and trained personnel providing diagnostic services.

  • Commitment to quality driving high individual consumer business share and customer retention.

Risks

  • 95.48% of its Revenue from Operations in Fiscal 2024 was generated from West Bengal, and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.

  • The securities of certain of its Promoter Group members have been suspended from trading on a recognized stock exchange in the past. The company cannot assure you that there will be no such instances in the future which may adversely affect its operations, reputation and ability to raise capital through further public issue of securities.

  • The diagnostics industry in India is highly competitive and its inability to compete effectively from other healthcare service providers may adversely affect its business, results of operations and financial condition. Further, as of Financial Year 2024, the market share of the Company in its major market which is East India is 1.15-1.30%.

  • The B2B segment contributed to 6.17% of its Revenue from Operations in Fiscal 2024 and any non-renewal or cancellation of its arrangements with its institutional customers, including hospitals, and Public-Private Partnership ("PPP") contracts may adversely affect its business, results of operations and financial condition.

  • Its Statutory Auditors have included certain emphasis of matters, and audit qualifications matters prescribed in the audit reports of the Company for Fiscals 2023 and 2024.

Company Promoters

Promoters Holding

Issue For IPO
12.29%
Pre Holding

61.07%

Post Holding

48.78%

Top Promoters Holding

Financials

All values in Cr

Mar-2022 Mar-2023 Mar-2024 3-Yr trend
Revenue 223.19 (59.40%) 190.13 (-14.80%) 218.71 (15.00%)
Gross Profit 48.28 (118.60%) 38.42 (-20.40%) 64.05 (66.70%)
Net Income 23.75 (268.80%) 6.52 (-72.60%) 23.63 (262.40%)
Assets 169.30 (18.60%) 252.78 (49.30%) 270.39 (7.00%)
Liabilities 19.33 (16.90%) 96.85 (401.00%) 90.98 (-6.10%)

Peers

Company Name Revenue (Cr) Net Profit (Cr) Assets (Cr) Liabilities (Cr) ROE EPS BVPS Current Ratio Debt to Assets
Suraksha Diagnostic Ltd 218.71 23.63 270.39 90.98 14.09 34.24 257.65 1.83 0.33
Dr Lal Pathlabs Ltd 2,226.64 357.74 2,455.96 2,455.96 19.34 43.05 225.85 14.56 0.04
Metropolis Healthcare Ltd 1,207.71 127.82 1,555.06 1,555.06 11.66 24.95 214.59 8.21 0.00
Vijaya Diagnostic Centre Ltd 547.81 118.83 982.75 982.75 18.08 11.62 64.48 12.09 0.00

Book Running Managers

  • ICICI Securities Ltd
  • Nuvama Wealth Management Ltd
  • SBI Capital Markets Ltd

Registrar & Transfer Agent

KFin Techologies Ltd

Karvy Selenium Tow-B,
31&32 Financial Dist,
Nanakramguda - Hyderabad-500032
Phone : 91-40-67162222 Fax: 91-40-23001153/23420814

Company Contact Information

Plot No DG-12/1 Action Area 1D,
Premieses No 02-0327 Rajarhat,
Kolkata - 700156
Phone : +91 33 6605 9750 Email : investors@surakshanet.com www.surakshanet.com

Offer Related Information

Initial public offering of 19,189,330 equity shares of face value of Rs. 2 each of Suraksha Diagnostic Limited (the "Company" or the "Issuer") for cash at a price of Rs. 441 per equity share (including a premium of Rs. 439 per equity share) (the "Offer Price") aggregating to Rs. 846.25 crores through an offer for sale of 19,189,330 equity shares of face value of Rs. 2 each aggregating to Rs. 846.25 crores, comprising 2,132,148 equity shares of face value of Rs. 2 each aggregating to Rs. 94.03... More

News

  • No Data Found.

Suraksha Diagno. FAQ's

The shares of Suraksha Diagno. were first listed on the stock exchanges on June 26, 2024.

The total issue size of the Suraksha Diagno. IPO was 1,10,00,000 shares, amounting to Rs. 132 crore. they

The minimum lot size for Suraksha Diagno. public issue was 125 shares.

The price band of the IPO of Suraksha Diagno. was Rs. 114 to Rs. 120 per equity share.

Suraksha Diagno. IPO is a public issue through which the company raised approximately Rs. 132 crore by issuing around 1.1 crore equity shares to the public. After a successful IPO, the company’s shares are currently listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), where they are freely traded without restrictions.

Bigshare Services Private Limited is the registrar and share transfer agent of Suraksha Diagno. IPO.

qr-code
login-icon

Take your research to the next level.
Login now to unlock Exclusive Features!

login-icon-1

Take your research to the next level.
Login now to unlock Exclusive Features!

Download Our App On: